Feb 25 |
An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 21% Undervalued
|
Feb 23 |
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
|
Feb 13 |
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
|
Feb 11 |
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
|
Feb 5 |
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
|
Jan 31 |
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
|
Jan 26 |
CSL's (ASX:CSL) investors will be pleased with their decent 60% return over the last five years
|
Jan 16 |
Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
|
Jan 10 |
Why Does China Remain Terrible at Soccer? Xi Jinping Has One Answer
|
Jan 3 |
CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
|